ReviewClinical endocrinology2025
Anti-Obesity Medication in the Management of Children and Adolescents With Obesity: Recent Developments and Research Gaps.
Review in Clinical endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The GLP-1 Agonist Exenatide Is Associated with Improved Adherence to Health Behavior and Lifestyle Treatment in Adolescents with Obesity: A Randomized Controlled Trial.Obesity facts · 2026Article
- Cardiovascular disease burden in children with obesity: A narrative review.International journal of cardiology. Cardiovascular risk and prevention · 2026Review
- A Growing Burden: Obesity's Impact on Cardiometabolic Disease Risk in Children and Adolescents.Current cardiology reports · 2026Review
- Use of obesity medications in a young pediatric patient with optic nerve hypoplasia and severe early-onset obesity: A case report.Obesity pillars · 2025Article
- Intersection between Eating Disorders and Obesity in Youth: Implications for Treatment.Current obesity reports · 2025Review
- Advancements and challenges in the management of obesity using pharmacotherapy (Review).Experimental and therapeutic medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPaediatric obesity is a global public health concern. While in most countries the incidence keeps rising, the need for effective and long-term management for children and adolescents living with this chronic, relapsing disease is pressing. Health behaviour and lifestyle treatment (HBLT) is recommended as first-line treatment.
methodsNarrative review.
resultsA new generation of recently approved anti-obesity medications (AOM) now has the potential to fill the gap between limited effects on body mass index (BMI) by HBLT alone and large effects by metabolic and bariatric surgery in adolescents with obesity aged 12 years and older. While, for semaglutide and phentermine/topiramate, effectiveness is substantial with relevant, but mostly mild to moderate adverse events, there is a gap in evidence regarding long-term effects and safety, effects on outcomes beyond BMI reduction and data for certain groups of patients, such as children < 12 years and minority groups. When integrating AOM treatment into national healthcare systems it should be offered as part of a comprehensive patient-centred approach.
conclusionThis article summarizes recent AOM developments, integration into paediatric obesity management, and identifies research gaps.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.